Journal article
Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria
A Haghiri, DJ Price, P Fitzpatrick, S Dini, M Rajasekhar, C Fanello, J Tarning, J Watson, NJ White, JA Simpson
Clinical Pharmacology and Therapeutics | WILEY | Published : 2023
DOI: 10.1002/cpt.3041
Abstract
The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria. Since 2015, the World Health Organization has recommended individual doses of 3 mg/kg for children weighing < 20 kg. Recently, the US Food and Drug Administration (FDA) has challenged this recommendation, based on a simulated pediatric population, and argued for a lower dose in younger children (2.4 mg/kg). In this study, we performed population pharmacokinetic (PK) modeling of plasma concentration data from 80 children with severe falciparum malaria in the Democratic Republic of Congo who were given 2.4 mg/kg of ARS intravenously. Bayesian..
View full abstractGrants
Awarded by Australian Centre of Research Excellence in Malaria Elimination
Funding Acknowledgements
The authors thank all participants from the REACH study as well as the clinical/laboratory staff involved. We would also like to thank the SMAC network who generously made their anonymized study data openly accessible. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.